Introduction
The development and therapeutic use of fully human monoclonal antibodies has been an elusive goal for many years, as currently there is no general way to activate human B cells against a human antigen of choice. The most common immunotherapeutic approach is to utilize antibodies from other non-human species that have been engineered to reduce their immunogenicity (e.g., chimeric or humanized murine antibodies) (1) (2) (3) . Alternatively, a closely related species, the macaque, has been used to produce PRIMA-TIZED® antibodies. Macaques are able to mount a high-affinity response to human antigens (4, 5) , and their immunoglobulin genes share a high degree of homology with human immunoglobulin sequences.
Phage display libraries, generated from naive human lymphocytes, have recently been employed and offer the possibility of identifying and selecting human antibodies against a human antigen of choice (6) (7) (8) (9) or antibodies have been selected from synthetic repertoires (10) .
Previously, we have shown that B cells from an immune donor producing antibodies to a predetermined viral antigen could be immortalized by boosting donor spleen cells during passage in a severe combined immunodeficiency disorder (SCID) mouse (11) . The target antigen in this case was the fusion protein (F-protein) from respiratory syncytial virus (RSV). Antigen-specific titers in the human spleen (hu-SPL)-SCIDs approached 2 x 106, and the subsequent immortalization process was highly efficient. In addition, the monoclonal antibodies isolated by this means were of high affinity and highly effective in in vitro functional inhibition tests. Two Epstein-Barr virus (EBV)-transformed B cell lines producing antibodies, RF-1 and RF-2, against the RSV fusion protein were established (11 
Materials and Methods
Generation of Anti-RSV Monoclonal Antibodies Establishment of the two B cell lines producing the antibodies RF-1 and RF-2 has been described elsewhere (11, 12) . Briefly, human spleen cells were primed with RSV F-protein in vitro prior to transfer into a SCID mouse. The resulting hu-SPL-SCIDs were subsequently boosted with Fprotein in adjuvant and developed B cell tumors in their spleens. Two such hu-SPL-SCIDs with high anti-F-protein IgG titers were sacrificed, B cell tumors from these animals removed, and the cells teased into a single-cell suspension in RPMI tissue culture medium containing 10% fetal bovine serum (FBS). F-protein-specific clones, RF-1 and RF-2, were established through limiting dilution clonings (see below).
RSV F-Protein F-protein was prepared by the method described by Walsh et al. (13) . Briefly, HEp-2 cells infected with the Long A strain of RSV were lysed using a buffer of phosphate-buffered saline (PBS) containing 1% (v/v) Triton X-100 and 1% (w/v) sodium deoxycholate. F-protein was purified from the crude cell lysate on an affinity column of a murine monoclonal anti-F antibody (Mab 858-1, Chemicon International, Temecula, CA) coupled to CNBr-activated Sepharose-4B (Pharmacia, Uppsala, Sweden, Cat. No. 17-0430-01) using standard procedure described by the manufacturer. The column was washed extensively with lysis buffer and purified F-protein was eluted from the column with 0.1 M glycine, pH 2.5, containing 0.1% (w/v) sodium deoxycholate. The eluate was neutralized immediately with 1 PCR Amplification cDNA produced by the SuperScript RT method was divided into aliquots and amplified by PCR using 5 U of Pfu polymerase (Stratagene, San Diego, CA) and 50 pmoles of 5' and 3' primer. The reaction mixtures were subjected to 40 rounds of amplification using the following protocol; 930C for 1.5 min, 540C for 2.5 min, and 720C for 3 min, followed by a final incubation of 720C for 5 min. cDNA produced by the rTth DNA polymerase method was divided into aliquots as above and amplified by PCR according to the manufacturer's directions. The rTth DNA polymerase functions as a DNA polymerase after the MnCl2 present in the cDNA reaction is chelated and MgCl2 is added. The reaction mixtures were incubated at 700C for 15 min and 950C for 3 min, followed by 35 cycles of amplification at 950C for 1 min and 600C for 1 min.
Ten microliters of the reaction mixture was run on an agarose gel to check for amplified fragments of the correct theoretical size (350 bp). All PCR reactions were set up in duplicate to ensure that any potential errors introduced by the polymerase reaction could be detected by DNA sequencing of the amplified fragments.
Cloning PCR Amplified Material into a Mammalian Expression Vector The PCR reactions were extracted with phenol/ chloroform and then digested with the appropri- Control primers designed to amplify the heavy-chain CHI region also failed to amplify the RF-1 and RF-2 cDNA. These same primers amplified the appropriate control fragment from a cDNA preparation from a different cell line. The failure of control primers as well as V region primers to amplify the appropriate region suggested the failure of Superscript to produce cDNA in the RT reaction, even though lightchain cDNA was successfully amplified.
PCR Amplification of cDNA from RF-1 and RF-2 Tumor Cell Lines Produced by Thermostable rTth DNA Polymerase Because the heavy-chain CHI region control primers as well as V region primers were unable to amplify a fragment from RF-1 and RF-2 mRNA, this suggested that Superscript RT was unable to produce cDNA from RF-1 and RF-2. By contrast, thermostable rTth DNA polymerase was capable of transcribing mRNA from RF-1 and RF-2, as evident from the PCR bands of approximately 350 bp, the expected size for an ampli- Fig. 1 . Amino acid sequence of the heavychain variable region from RF-1 (above) compared to RF-2 (below). CDR regions are underlined. Figure 1 . Comparative analysis of VH genes with immunoglobulin database sequences was performed using the DNAPLOT program from Althaus and Mueller (22) . RF-1 and RF-2 VH gene sequences showed that they were both from the VH2 heavy-chain gene family, confirming the preferential amplification by VH2 primers by PCR. Further analysis suggested that RF-1 VH originated from the V2-26/DP-26+ germ-line sequence and RF-2 VH sequence from the DP-28/ VH2-MC1 germ-line V gene. Both these germline genes are closely related. Both RF-1 and RF-2 genes showed a high degree of homology with one another; however, comparison of their complementarity determining regions (CDR) 3 regions showed distinct differences (Fig. 1) . Both RF-1 and RF-2 VH genes used separate D region genes (DA5 and D2, respectively) and have different extents of N region addition, thus giving rise to distinctly different CDR3 regions. The same JH4 gene appears to have been used by both RF-1 and RF-2. VL genes from at least two independent PCR reactions from both RF-1 and RF-2 were sequenced. The sequence of the VL genes is shown in Figure 2 . Both VL genes were from the K III family, which confirmed the results obtained using different VK gene family primers and they were highly homologous with one another.
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Further analysis of the VL genes suggested, in fact, that they had both originated from the same germ-line gene (DPK9/012) but utilized different J region genes. RF-1 utilized JK1 and RF-2 used JK2. Although RF-1 and RF-2 apparently used the same V gene, giving almost identical frameworks, the CDR regions, particularly CDR2 and CDR3, differed significantly.
Expression Levels of RF-1 and RF-2 MAbs by CHO Transfectants CHO transfectants selected in G418 were assayed by ELISA for antibody production. The highest-producing cRF-1 clones were expanded and subjected to two rounds of methotrexate-induced amplification, first with 5 nM, then 50 nM methotrexate. The highest-producing cRF-2 clones were expanded and subjected to three rounds of methotrexate amplification at 5 nM, 50 nM, and 500 nM methotrexate. Each round of amplification was performed by cloning at limiting dilution and identifying the highest producers. The cRF-1-producing clone after two rounds of amplification had a specific cellular productivity of 45 pg/cell/day. The cRF-2-producing clone after three rounds of amplification had a specific cellular productivity of 42 pg/cell/day.
Binding Characteristics and Affinity of Recombinant cRF-1 and cRF-2 Produced by CHO Cells AFFINITY MEASUREMENTS. The binding of both RF-1 and RF-2 to F-protein was strong and specific. Halfmaximal responses to F-protein were achieved at concentrations of 0.5 and 2 ng/ml, respectively (Fig. 3A,B) , whereas there was no binding to a series of control proteins (11) . The discrepancy between the apparent binding activities of B cell-produced RF-2 (purified prior to single-cell cloning) and CHO cell-produced cRF-2 is likely due to the presence of contaminating non-F-protein-specific antibodies, as indicated by isoelectric focusing gels (not shown).
The Kds of cRF-1 and cRF-2 for binding to purified F- protein was determined by Scatchard plots (Fig. 4) . The Kd of cRF-1 was determined to be 0.1 nM, whereas the Kd of cRF-2 was determined to be 0.07 nM. This correlates well with the value determined on the B cell-produced MAbs, prior to gene cloning, that were measured as 0.1 nM and 1 nM, respectively, where the latter was an oligoclonal population.
VIRAL NEUTRALIZATION STUDIES. To determine whether the antibodies had virus neutralizing activity, they were subjected to an in vitro neutralization assay: live virus was preincubated 
Discussion
The methodology described here, together with previous publications (11, 12) CHO system rather than as hybridomas because of stability, high production levels, and low viral load.
The technique described here represents a way of immortalizing B cell clones prior to Ig gene cloning and expression in CHO cells. Both RF-1 and RF-2 mRNA were resistant to amplification by standard PCR conditions. However, they were easily amplified using a thermostable RT. An alternative method for isolation and selection of human Ig genes is phage display technology. In this system, RNA is isolated from a pool of human B cells, converted to cDNA, and expressed as protein on the surface of bacteriophage. Since the standard conditions of PCR amplification usually employed for phage display technology are similar to those for cloning into mammalian expression vectors, it is likely that the VH2 genes described here would have been missed. The literature seems to support this, as antibodies derived from VH2 genes are infrequently reported in the literature (24-26; J. Marks, personal communication). Thus, VH2 may be underrepresented because of resistance to common cloning methods. If VH2 genes are preferentially used to target specific antigens and these genes resist cloning using standard PCR methodology, then potentially useful antibodies may be lost. The resulting repertoire might be skewed to sequences that match the primers and/or the reverse transcriptase used rather than reflect the relative abundance, affinity, and/or activity of antibodies represented in vivo. Whether this is specific to the two VH2 genes described here or whether it represents a general feature of VH2 genes is unknown. There may be a secondary structure associated with VH2 mRNA that precludes their reverse transcription without the use of a high-temperature RT. In a system such as the one described above, where antigen is used to stimulate and expand B cells, genes that may be difficult to clone can be more easily rescued.
Fully human antibodies with the capability of neutralizing RSV could have a major impact on the immunotherapy of this disease. The current method for treatment of RSV is by intravenous Ig (IVIG) (27) , of which only a small fraction is RSV-specific. The use of a recombinant MAb would result in a more specific therapy. It would have less variability and more defined effector functions than IVIG preparations. Data from our in vitro studies show a 124-fold better neutralizing titer for strain A RSV than the equivalent amount of Ig from a high-titer anti-RSV serum. The activity of cRF-2 also compares favorably with two anti-F-protein MAbs: one in preclinical development (28) and another currently in the clinic (29) . Thus, a high specific neutralizing activity would result in a lower effective dose. This, combined with the commercial advantage of a CHO-producing clone that may potentially produce 500 mg/L in a bioreactor, makes cRF-2 administration an economically feasible method for the treatment of RSV infections.
